4,5-dihydro-5-methyl-4-phenyl-1-p-tolyl-1,4-epoxy-1H-2,3-benzodioxepin | 256530-35-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 4,5-dihydro-5-methyl-4-phenyl-1-p-tolyl-1,4-epoxy-1H-2,3-benzodioxepin
• 英文别名: 8-Methyl-1-(4-methylphenyl)-9-phenyl-10,11,12-trioxatricyclo[7.2.1.02,7]dodeca-2,4,6-triene
• CAS: 256530-35-5
• 化学式: C₂₃H₂₀O₃
• 分子量: 344.41
• InChiKey: RJLLJFODOZUNQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-methyl-2-phenyl-3-p-tolylindene 在 ozone 作用下， 以 二氯甲烷 为溶剂， 以70%的产率得到4,5-dihydro-5-methyl-4-phenyl-1-p-tolyl-1,4-epoxy-1H-2,3-benzodioxepin
  参考文献：
  名称：

  Ozonide compounds with inhibitory activity for urokinase production and angiogenesis

  摘要：

  该发明提供了一种尿激酶产生抑制剂或血管生成抑制剂，其包括作为活性成分的一种由式（1）表示的臭氧化物衍生物，以及使用该抑制剂的预防或治疗方法，其中A是氧原子或N—R（其中R是苯基或苯基，其取代基为1至6个碳原子的较低烷基，1至6个碳原子的较低烷氧基或卤原子）；B是羰基或—R4；当A是氧原子时，R1是氢原子等，R2是苯基等，R3是氢原子等，B是羰基或—R4，R4是氢原子等，R5是氢原子等；当A是N—R时，R1是氢原子等，R2是氢原子等，R3是氢原子等，B是—R4，R4是氢原子等，R5是氢原子等。

  公开号：

  US06365610B1

文献信息

• UROKINASE PRODUCTION INHIBITORS, ANGIOGENESIS INHIBITORS AND METHODS OF PREVENTION OR TREATMENT WITH BOTH
  申请人：TAIHO PHARMACEUTICAL COMPANY LIMITED

  公开号：EP1033130A1

  公开（公告）日：2000-09-06

  The invention provides a urokinase production inhibitor or angiogenesis inhibitor comprising as an active component an ozonide derivative represented by the formula (1), and method of prevention or therapy using the inhibitor wherein A is an oxygen atom or N-R (wherein R is phenyl or phenyl having as a substituent lower alkyl having 1 to 6 carbon atoms, lower alkoxyl having 1 to 6 carbon atoms or a halogen atom); B is an oxo group or -R4; and (1) when A is an oxygen atom, R1 is a hydrogen atom, etc., R2 is phenyl, etc., R3 is a hydrogen atom, etc., B is an oxo group or -R4, R4 is a hydrogen atom, etc., R5 is a hydrogen atom, etc.; (2) when A is N-R, R1 is a hydrogen atom, etc., R2 is a hydrogen atom, etc., R3 is a hydrogen atom, etc., B is -R4, R4 is a hydrogen atom, etc., R5 is a hydrogen atom, etc.

  本发明提供了一种尿激酶生成抑制剂或血管生成抑制剂，其活性成分包括由式(1)表示的臭氧衍生物，以及使用该抑制剂进行预防或治疗的方法 其中 A 是氧原子或 N-R(其中 R 是苯基或具有 1 至 6 个碳原子的低级烷基、具有 1 至 6 个碳原子的低级烷氧基或卤原子作为取代基的苯基)；B 是氧代基团或 -R4；以及 (1) 当 A 是氧原子时，R1 是氢原子等，R2 是苯基等、R3 是氢原子等，B 是氧代基团或-R4，R4 是氢原子等，R5 是氢原子等；(2) 当 A 是 N-R，R1 是氢原子等，R2 是氢原子等，R3 是氢原子等，B 是-R4，R4 是氢原子等，R5 是氢原子等。
• INHIBITOR OF UROKINASE PRODUCTION AND OF ANGIOGENESIS AND ITS THERAPEUTIC USE
  申请人：TAIHO PHARMACEUTICAL COMPANY LIMITED

  公开号：EP1033130B1

  公开（公告）日：2004-04-21
• NOVEL CYCLOHEXENYL PHENYL DIAZEPINES AS VASOPRESSIN AND OXYTOCIN RECEPTOR MODULATORS
  申请人：Wyeth

  公开号：EP1377584A1

  公开（公告）日：2004-01-07
• US6365610B1
  申请人：——

  公开号：US6365610B1

  公开（公告）日：2002-04-02
• [EN] NOVEL CYCLOHEXENYL PHENYL DIAZEPINES VASOPRESSIN AND OXYTOCIN RECEPTOR MODULATORS<br/>[FR] NOUVELLES CYCLOHEXENYL-PHENYL-DIAZEPINES MODULATRICES DES RECEPTEURS DE LA VASOPRESSINE ET DE L'OCYTOCINE
  申请人：WYETH CORP

  公开号：WO2002083681A1

  公开（公告）日：2002-10-24

  The present invention provides novel tricyclic diazepine compounds and methods and pharmaceutical compositions utilizing them for the treating or preventing disorders including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, congestive heart failure or for inducing temporary delay of urination, and in conditions with increased vascular resistance and coronary vasoconstriction; and for the treating or preventing disorders remedied or alleviated by oxytocin antagonist activity, including suppression of preterm labor, dysmenorrhea, endometritis, and for suppressing labor at term prior to caesarean delivery. These compounds are also useful in enhancing fertility rates, enhancing survival rates and synchronising estrus in farm animals; and treatment of disfunction of the oxytocin system in the central nervous system including obsessive compulsive disorder (OCD) and neuropsychiatric disorders.